SecBot SecBot
144 ·Filed Oct 28, 2026

NVS

NOVARTIS AG
NEUTRAL
Impact 2/10
Horizonimmediate Processed1d 15h ago SEC0001959173-26-007516
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The proposed sale is small relative to the company's market cap and appears to be a routine insider transaction related to equity compensation. Monitor for any subsequent Form 4 filings to confirm execution, but no material impact on the stock is expected.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled: T+1d
NVS ▲ +3.22% at T+1d
NEUTRAL call +3.22% · α vs SPY +3.60% · entry $156.08 → $161.10
Next anchor: T+5d in 5d
Entry = T+0 close
Oct 28, 2026
via day close
T+1d
+3.22%
call +3.22% · α +3.60%
$161.10
settled 18h ago
T+5d
Pending
in 5d
T+20d
Pending
in 26d
T+60d
Pending
in 3mo

Price Chart

Loading chart...

Executive Summary

Victor Bulto Carulla, an officer of Novartis AG, filed a Form 144 notice of intent to sell 6,000 American Depositary Shares (ADS) with an estimated aggregate market value of approximately $933,180. The shares were acquired through restricted stock vesting events between January 2024 and January 2026. The proposed sale is scheduled for October 28, 2026, and is a routine insider transaction for tax or diversification purposes.

Key Facts

  • Insider: Victor Bulto Carulla, an officer of Novartis AG
  • Proposed sale of 6,000 American Depositary Shares (ADS)
  • Estimated aggregate market value: approximately $933,180
  • Shares acquired via restricted stock vesting on multiple dates from January 2024 to January 2026
  • Proposed sale date: October 28, 2026
  • Broker: Fidelity Brokerage Services LLC
  • Market cap of Novartis AG: $293.5B

Financial Impact

Sale of 6,000 ADS valued at ~$933,180, representing a negligible fraction of the company's $293.5B market cap

dilution

Risk Factors

  • Form 144 is an intent to sell; the sale may not be executed
  • Insider selling could be perceived negatively if it signals reduced confidence, but the amount is immaterial here

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
47% bullish (34 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-007516
Document: 0001959173-26-007516-index.html0001959173-26-007516
Document: 0001959173-26-007516.txt0001959173-26-007516
14 reports for NVS
Performance horizon
67% Hit rate @ T+1 4 of 6 directional calls Went positive at some point 5 of 6 best @ T+60▲ +6.86%Jul 1, 2026
Filters
Rows
Reports for NVS, sortable and filterable
TypeNow
Oct 28, 2026
1d ago
144
NEUTRAL ★ 2/10
$156.08 $161.10▲ +3.22%▲ +3.60%$161.10 (+3.22%)
Oct 27, 2026
2d ago
6-K
MIXED ★ 6/10
$156.86 $156.08▼ −0.50%▼ −0.84%$161.10 (+2.70%)
Oct 15, 2026
15d ago
Court Ruling
NEUTRAL ★ 2/10
$150.62 $150.20▼ −0.28%▼ −0.70%$161.10 (+6.96%)
Oct 13, 2026
17d ago
Court Ruling
BEARISH ★ 5/10
$146.88 $150.38▼ −2.38%▼ −2.10%$161.10 (−9.68%)
Sep 22, 2026
5w ago
Institutional Cluster
MIXED ★ 4/10
$141.28 $142.71▲ +1.01%▲ +1.73%$161.10 (+14.03%)
Sep 4, 2026
7w ago
6-K
BEARISH ★ 6/10
$137.70 $137.48▲ +0.16%▼ −0.30%$161.10 (−16.99%)
Sep 1, 2026
8w ago
6-K
BULLISH ★ 7/10
$161.25 $162.46▲ +0.75%▲ +0.31%$161.10 (−0.09%)
Aug 4, 2026
12w ago
Court Ruling
NEUTRAL ★ 2/10
$154.44 $154.21▼ −0.15%▲ +0.01%$161.10 (+4.31%)
Jul 28, 2026
13w ago
Court Ruling
NEUTRAL ★ 1/10
$158.83 $158.44▼ −0.25%▼ −1.92%$161.10 (+1.43%)
Jul 21, 2026
14w ago
6-K
NEUTRAL ★ 4/10
$153.87 $153.08▼ −0.51%▼ −0.40%$161.10 (+4.70%)
Showing 10 of 14

US Market Status

Market Closed · Opens in 7h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 28, 2026